A novel test for IGT utilizing metabolite markers of glucose tolerance.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Sage Country of Publication: United States NLM ID: 101306166 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1932-2968 (Electronic) Linking ISSN: 19322968 NLM ISO Abbreviation: J Diabetes Sci Technol Subsets: MEDLINE
    • Publication Information:
      Publication: 2014- : Thousand Oaks, CA : Sage
      Original Publication: Foster City, CA : Diabetes Technology Society
    • Subject Terms:
      Insulin Resistance*; Biomarkers/*analysis ; Blood Glucose/*analysis ; Diabetes Mellitus, Type 2/*diagnosis ; Diabetes Mellitus, Type 2/*metabolism ; Glucose Intolerance/*diagnosis ; Glucose Intolerance/*metabolism; Adult ; Aged ; Biomarkers/metabolism ; Cardiovascular Diseases/etiology ; Cardiovascular Diseases/metabolism ; Cohort Studies ; Diabetes Mellitus, Type 2/complications ; Female ; Glucose Tolerance Test/standards ; Humans ; Male ; Middle Aged ; Predictive Value of Tests ; Risk Factors
    • Abstract:
      The oral glucose tolerance test (OGTT) is the only method to diagnose patients having impaired glucose tolerance (IGT), but its use has diminished considerably in recent years. Metabolomic profiling studies have identified a number of metabolites whose fasting levels are associated with dysglycemia and type 2 diabetes. These metabolites may serve as the basis of an alternative test for IGT. Using the stable isotope dilution technique, quantitative assays were developed for 23 candidate biomarker metabolites. These metabolites were measured in fasting plasma samples taken just prior to an OGTT from 1623 nondiabetic subjects: 955 from the Relationship between Insulin Sensitivity and Cardiovascular Disease Study (RISC Study; 11.7% IGT) and 668 subjects from the Diabetes Mellitus and Vascular Health Initiative (DMVhi) cohort from the DEXLIFE project (11.8% IGT). The associations between metabolites, anthropometric, and metabolic parameters and 2hPG values were assessed by Pearson correlation coefficients and Random Forest classification analysis to rank variables for their ability to distinguish IGT from normal glucose tolerance (NGT). Multivariate logistic regression models for estimating risk of IGT were developed and evaluated using AUCs calculated from the corresponding ROC curves. A model based on the fasting plasma levels of glucose, α-hydroxybutyric acid, β-hydroxybutyric acid, 4-methyl-2-oxopentanoic acid, linoleoylglycerophosphocholine, oleic acid, serine and vitamin B5 was optimized in the RISC cohort (AUC = 0.82) and validated in the DMVhi cohort (AUC = 0.83). A novel, all-metabolite-based test is shown to be a discriminate marker of IGT. It requires only a single fasted blood draw and may serve as a more convenient surrogate for the OGTT or as a means of identifying subjects likely to be IGT.
      (© 2014 Diabetes Technology Society.)
    • Comments:
      Comment in: J Diabetes Sci Technol. 2015 Jan;9(1):77-9. (PMID: 25427966)
    • References:
      Diabetes Care. 2004 Jun;27(6):1417-26. (PMID: 15161798)
      Diabetes Res Clin Pract. 2007 Sep;77(3):459-64. (PMID: 17350133)
      Acta Clin Belg. 2006 Mar-Apr;61(2):64-8. (PMID: 16792336)
      J Diabetes Sci Technol. 2013 Jan 01;7(1):100-10. (PMID: 23439165)
      Diabetes Care. 2012 Aug;35(8):1749-56. (PMID: 22563043)
      BMC Bioinformatics. 2011 Mar 17;12:77. (PMID: 21414208)
      Diabetes Care. 2003 Mar;26(3):725-31. (PMID: 12610029)
      Diabetes Care. 2010 Sep;33(9):2077-83. (PMID: 20573752)
      Diabetes Care. 2014 Jan;37 Suppl 1:S14-80. (PMID: 24357209)
      Diabetologia. 1985 Jul;28(7):412-9. (PMID: 3899825)
      Prim Care Diabetes. 2008 Sep;2(3):147-53. (PMID: 18779039)
      Med Clin North Am. 2011 Mar;95(2):327-39, vii-viii. (PMID: 21281836)
      Diabetes Care. 2003 Jul;26(7):2058-62. (PMID: 12832313)
      Diabetologia. 2013 Jul;56(7):1489-93. (PMID: 23584433)
      Diabetes. 2010 Jul;59(7):1585-90. (PMID: 20424232)
      Mol Syst Biol. 2012;8:615. (PMID: 23010998)
      Diabetes. 1996 Nov;45(11):1585-93. (PMID: 8866565)
      Diabetologia. 2011 Jun;54(6):1507-16. (PMID: 21424899)
      Diabetes. 2013 Feb;62(2):639-48. (PMID: 23043162)
      Diabetologia. 2009 May;52(5):818-24. (PMID: 19224196)
      Diabetes Care. 2010 Sep;33(9):2104-9. (PMID: 20573754)
      Diabetes. 2013 May;62(5):1730-7. (PMID: 23160532)
      Science. 1992 Oct 30;258(5083):766-70. (PMID: 1439783)
      PLoS One. 2010 May 28;5(5):e10883. (PMID: 20526369)
      Diabetes. 2013 Dec;62(12):4270-6. (PMID: 23884885)
      BMJ. 2007 Feb 10;334(7588):299. (PMID: 17237299)
      Eur J Epidemiol. 2011 Oct;26(10):779-87. (PMID: 21947790)
      Diabetes Care. 2010 Oct;33(10):2190-5. (PMID: 20628087)
      Diabetes Res Clin Pract. 2014 Nov;106(2):383-9. (PMID: 25125339)
      N Engl J Med. 2002 Feb 7;346(6):393-403. (PMID: 11832527)
      Diabetes. 2009 May;58(5):1212-21. (PMID: 19223598)
      J Clin Invest. 2013 Oct;123(10):4309-17. (PMID: 24091325)
      Biometrics. 1988 Sep;44(3):837-45. (PMID: 3203132)
      Diabetologia. 2004 Mar;47(3):566-570. (PMID: 14968294)
    • Contributed Indexing:
      Keywords: IGT; OGTT; biomarkers; metabolomics
    • Accession Number:
      0 (Biomarkers)
      0 (Blood Glucose)
    • Publication Date:
      Date Created: 20140928 Date Completed: 20151214 Latest Revision: 20211021
    • Publication Date:
      20221213
    • Accession Number:
      PMC4495543
    • Accession Number:
      10.1177/1932296814553622
    • Accession Number:
      25261439